

# Priority and watchlist medicines for in-licensing by the Medicines Patent Pool



Scan to access  
most recent version



## HIV

lenacapavir *Gilead*

broadly neutralising antibodies  
for HIV post-natal prophylaxis

*Multiple patent holders*

cabotegravir & rilpivirine *ViiV & Janssen*

doravirine *MSD*

islatravir *Merck*



## TUBERCULOSIS

quabodepistat *Otsuka*

BTZ-043 *Univ. of Munich & DZIF*

delpazolid *LegoChem BioSciences*

ganfeborole *GSK*

macozinone *EPFL*

sudapyridine *Shanghai Jiatan Biotech*



## PANDEMIC & EPIDEMIC THREATS

baloxavir marboxil *Roche*



## VIRAL HEPATITIS

bulevirtide *Gilead*



## DIABETES, CARDIOVASCULAR & METABOLIC DISORDERS

Incretin-based therapies (incl. GLP1 RA)

*Multiple patent holders*

including semaglutide *Novo Nordisk*

tirzepatide *Eli Lilly*

cardiovascular fixed-dose  
combination therapies

*Multiple patent holders*



## ONCOLOGY

### LUNG CANCER

aumolertinib

*Revolution Medicines*

osimertinib *Astrazeneca*

adagrasib *Mirati*

lazertinib *Janssen*

sotorasib *Amgen*

### BREAST CANCER

abemaciclib *Eli Lilly*

ribociclib *Novartis*

trastuzumab SQ *Roche*

### HAEMATOLOGICAL MALIGNANCIES

ibrutinib *Janssen*

zanubrutinib *Beigene*

### PROSTATE CANCER

apalutamide *Janssen*

darolutamide *Bayer*

### MULTIPLE CANCER INDICATIONS

Immune checkpoint  
inhibitors

*Multiple patent holders*

including pembrolizumab *MSD*

oral paclitaxel /  
encequidar *Athenex*



## CHILDHOOD ONSET DISEASES

### RESPIRATORY SYNCYTIAL VIRUS

nirsevimab *Astrazeneca/Sanofi*

clesrovimab *MSD*

### CYSTIC FIBROSIS

elexacaftor/tezacaftor/ivacaftor *Vertex*

PRIORITY LIST

WATCHLIST